Jazz Pharmaceuticals Says on February 27, 2015, FDA Notified Co's Unit of Approval of Risk Evaluation and Mitigation Strategy for Xyrem, FDA Concluded Xyrem REMS Meets Applicable Statutory Standards
Charles Gross